key: cord-320067-929h6arn
authors: Facheris, Paola; Valenti, Mario; Pavia, Giulia; Gargiulo, Luigi; Narcisi, Alessandra; Costanzo, Antonio; Borroni, Riccardo G.
title: Complicated coronavirus disease 2019 (COVID‐19) in a psoriatic patient treated with ixekizumab
date: 2020-06-18
journal: Int J Dermatol
DOI: 10.1111/ijd.15008
sha: 
doc_id: 320067
cord_uid: 929h6arn

nan

90%, and thoracic ultrasound was consistent with bilateral interstitial pneumonia; chest x-ray did not show lung opacities or pleural effusion. The patient was hospitalized and treated with hydroxychloroquine 400 mg BID p.o. the first day followed by 200mg BID, ceftriaxone 1g BID IM, and noninvasive continuous positive airway pressure (CPAP) in courses of prone ventilation. Antivirals were not given because of risk of arrhythmia. Fever remitted after 14 days, enabling transition from CPAP to low-flow oxygen. The patient was discharged after 22 days, with 97% oxygen saturation on walking test. Two repeated SARS-CoV-2 nasopharyngeal swabs resulted negative 30 days from diagnosis.

COVID-19 is caused by the SARS-CoV-2 virus, a new variant beta-coronavirus first isolated from the bronchoalveolar lavage fluid from patients with interstitial pneumonia. On January 30, 2020, the SARS-CoV-2 outbreak was declared a public health emergency of international concern. COVID-19 is characterized most commonly by fever and cough, although the clinical picture may range from completely asymptomatic to bilateral interstitial pneumonia. About 20% of patients develop acute respiratory distress syndrome (ARDS). Risk of severe complications and case fatality rate (CFR) are highest in the elderly, immunosuppressed, and those with chronic diseases. 

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

The Treatment Guideline for COVID-19 from Government in Chinese

Chinese Trial Clinical Registry.A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia

Should biologics for psoriasis be interrupted in the era of COVID-19?